Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.
Hepatol Res
; 53(2): 172-178, 2023 Feb.
Article
in En
| MEDLINE
| ID: mdl-36214071
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Language:
En
Journal:
Hepatol Res
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: